论文部分内容阅读
目的链霉素在结核病治疗中作为一线药物广泛使用,我国已经使用50年以上。本文主要研究结核分枝杆菌链霉素耐药基因rpsL和rrs基因突变检测对链霉素耐药的相关性。方法 205株结核分枝杆菌临床分离株(经常规方法证实,125株为链霉素耐药,80株为敏感),测定链霉素最小抑菌浓度(MIC),测序法检测rpsL和rrs基因突变。结果 84%(105/125)的链霉素耐药株携有rpsL或/和rrs基因突变,其中rpsL基因突变占大多数(76.8%,96/125)。对105株带有基因突变的菌株的分析表明,rpsL,rrs基因的突变类型与MIC之间未见密切关系。80株敏感株未检出基因突变。结论结核分支杆菌链霉素耐药相关基因rpsL和rrs突变在结核分枝杆菌链霉素耐药中起主要作用。
Purpose Streptomycin is widely used as a first-line drug in the treatment of tuberculosis and has been used for more than 50 years in our country. This paper mainly studies the relationship between streptomycin resistance and mycobacterium tuberculosis streptomycin resistance gene rpsL and rrs gene mutation detection. Methods Totally 205 clinical isolates of Mycobacterium tuberculosis (confirmed by routine method, 125 were streptomycin resistant and 80 were sensitive), the minimum inhibitory concentration (MIC) of streptomycin was determined, and the rpsL and rrs genes were detected by sequencing mutation. Results 84% (105/125) streptomycin resistant strains carried rpsL or / and rrs gene mutations, of which rpsL gene mutations accounted for the majority (76.8%, 96/125). The analysis of 105 strains with gene mutation showed that the type of mutation of rpsL and rrs genes was not closely related to MIC. 80 strains were not detected gene mutation. Conclusion The mutations of rpsL and rrs related to streptomycin resistance in Mycobacterium tuberculosis play a major role in streptomycin resistance in Mycobacterium tuberculosis.